Efforts to develop effective treatments for metastatic breast cancer, which is currently incurable, continue with numerous promising clinical trials. Despite this, finding a cure is likely a long way off due to the disease’s complexity. Notable progress includes the FDA approval of Stemline Therapeutics’ targeted therapy, elacestrant, for certain advanced metastatic breast cancers, and promising results from AstraZeneca’s phase 3 trial for HER2-low metastatic breast cancer using trastuzumab deruxtecan. Emerging strategies leveraging AI and machine learning in cancer imaging also show promise.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
